📊 CSCIF Key Takeaways
Is COSCIENS Biopharma Inc. (CSCIF) a Good Investment?
COSCIENS Biopharma lacks sufficient financial data to assess fundamental health, with only 1 metric available and no recent SEC filings. The company is inactive or non-reporting, making it impossible to evaluate profitability, liquidity, or operational performance.
COSCIENS’ fundamentals remain weak: full-year 2025 revenue fell to $7.5 million from $9.6 million in 2024, and the company still posted a $10.4 million net loss despite aggressive cost reductions. The balance of evidence suggests a shrinking business that is improving its burn rate, but the March 2026 decision to stop funding the German subsidiaries and effectively walk away from the loss-making biopharma unit underscores execution strain and limited growth quality.
Why Buy COSCIENS Biopharma Inc. Stock? CSCIF Key Strengths
- No strengths identified
- Operating expenses fell materially in 2025, showing management can reduce burn and right-size the cost base
- The active ingredients business remains the core revenue engine and serves established skincare-related end markets
- Year-end 2025 cash of $7.3 million provides some near-term liquidity while restructuring actions continue
CSCIF Stock Risks: COSCIENS Biopharma Inc. Investment Risks
- Complete absence of financial data - no revenue, earnings, or balance sheet information available
- No recent SEC filings or data freshness - company appears non-reporting or dormant
- Zero insider trading activity in past 90 days indicates lack of management confidence or company inactivity
- Impossible to assess liquidity, solvency, or operational viability without fundamental financial statements
- OTC listing with no reporting requirements compounds lack of transparency
- Revenue declined year over year in 2025, indicating weak top-line momentum even after the merger
- The company remains unprofitable, with losses still exceeding annual revenue and limited evidence of durable operating leverage
- Strategic retrenchment is severe: the German subsidiaries entered insolvency-related proceedings, and the company may surrender Macrilen-related rights while relying heavily on a narrow base business
Key Metrics to Watch
- SEC filing activity and latest 10-K or 10-Q submission date
- Revenue and net income upon resumption of reporting
- Cash position and runway given apparent lack of operations
- Quarterly revenue and gross margin in the active ingredients segment
- Cash burn and ending cash balance after the German subsidiary exit
COSCIENS Biopharma Inc. (CSCIF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CSCIF Profit Margin, ROE & Profitability Analysis
CSCIF vs Consumer Sector: How COSCIENS Biopharma Inc. Compares
How COSCIENS Biopharma Inc. compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is COSCIENS Biopharma Inc. Stock Overvalued? CSCIF Valuation Analysis 2026
Based on fundamental analysis, COSCIENS Biopharma Inc. has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
COSCIENS Biopharma Inc. Balance Sheet: CSCIF Debt, Cash & Liquidity
CSCIF Revenue Growth, EPS Growth & YoY Performance
CSCIF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for COSCIENS Biopharma Inc. (CIK: 0001113423)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CSCIF
What is the AI rating for CSCIF?
COSCIENS Biopharma Inc. (CSCIF) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CSCIF's key strengths?
Claude: . ChatGPT: Operating expenses fell materially in 2025, showing management can reduce burn and right-size the cost base. The active ingredients business remains the core revenue engine and serves established skincare-related end markets.
What are the risks of investing in CSCIF?
Claude: Complete absence of financial data - no revenue, earnings, or balance sheet information available. No recent SEC filings or data freshness - company appears non-reporting or dormant. ChatGPT: Revenue declined year over year in 2025, indicating weak top-line momentum even after the merger. The company remains unprofitable, with losses still exceeding annual revenue and limited evidence of durable operating leverage.
What is CSCIF's revenue and growth?
COSCIENS Biopharma Inc. reported revenue of N/A.
Does CSCIF pay dividends?
COSCIENS Biopharma Inc. does not currently pay dividends.
Where can I find CSCIF SEC filings?
Official SEC filings for COSCIENS Biopharma Inc. (CIK: 0001113423) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CSCIF's EPS?
COSCIENS Biopharma Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CSCIF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, COSCIENS Biopharma Inc. has a SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CSCIF stock overvalued or undervalued?
Valuation metrics for CSCIF: ROE of N/A (sector avg: 18%), net margin of N/A (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy CSCIF stock in 2026?
Our dual AI analysis gives COSCIENS Biopharma Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CSCIF's free cash flow?
COSCIENS Biopharma Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does CSCIF compare to other Consumer stocks?
Vs Consumer sector averages: Net margin N/A (avg: 8%), ROE N/A (avg: 18%), current ratio N/A (avg: 1.5).